Mavrilimumab
Based on 1 Customer Validation
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.37%
- No. CAS: 1085337-57-0
- Peso molecular:143.168 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
IC50 & Target
CSF2Ra/GM-CSFRa/CD116
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey models[2]
-
Dosage:3-100 mg/kg
-
Administration:iv, once a week for at least 11 weeks
-
Result:Produced foam cells in the lungs.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded Mavrilimumab on AHC2 biosensor, can bind GM-CSF R alpha Protein, Human (HEK293, His, HY-P7783) with an affinity constant of 7.867E-10 M as determined in BLI assay. -
Flow Cytometry analysis of Hela cells labelling GM-CSFRa (red) with Mavrilimumab (anti-GM-CSFRa) (HY-P99031). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG4 (S228P) lambda1(HY-P99987). Black-Unlabelled control, cells without incubation with primary antibody.
Product Details
-
No. CAS 1085337-57-0
-
Accession P15509
-
Synonyms CAM 3001
-
Peso molecular 143.168 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG4 lambda
-
Recommend Isotype Controls
-
Format
-
Human IgG4 lambda2
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Pureza
98.37%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Envío
Shipping with dry ice.
Pureza y Documentación
Referencias
[1]. Paul C Cremer, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-e41 [Content Brief]
[2]. Ryan PC, et al., Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety. Toxicol Appl Pharmacol. 2014 Sep 1;279(2):230-9. [Content Brief]
Hot Topics
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics The Tumor Microenvironment: A Pro-Tumor Niche and Therapeutic Target in Cancer
Cancer is not a single mass of cancer cells, but a complex ecosystem, the tumor microenvironment (TME).
2025-10-23
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)